An allergen inactivation method includes an inactivation step of inactivating an allergen present in a reaction system by reduction via a reduced redox protein, and a reduction process of reducing an oxidized redox protein produced by oxidation of the reduced redox protein in the inactivating to the reduced redox protein by donating an electron from an electrode connected to an external power supply outside the reaction system to the oxidized redox protein.

The present disclosure pertains to compositions comprising anti-VEGF proteins.

The present disclosure pertains to compositions comprising anti-VEGF proteins.

The present invention belongs to the field of biomedicine, and provided is a PEG-modified polypeptide capable of inhibiting gp96, which comprises PIBC linked by a covalent bond and PEG having an average molecular weight of 20,000-40,000. Further provided is a method for preparing the PEGylated polypeptide, a drug or preparation comprising the PEGylated polypeptide, and a use of the PEGylated polypeptide.

The present invention belongs to the field of biomedicine, and provided is a PEG-modified polypeptide capable of inhibiting gp96, which comprises PIBC linked by a covalent bond and PEG having an average molecular weight of 20,000-40,000. Further provided is a method for preparing the PEGylated polypeptide, a drug or preparation comprising the PEGylated polypeptide, and a use of the PEGylated polypeptide.

The present disclosure relates to methods of re-oxidizing an antigen-binding protein.

An object of the present invention is to provide a novel method having high efficiency and versatility for a peptide thioester and peptide. The present invention provides a method for producing a peptide thioester, comprising the steps of: (1) providing a peptide thioester having a CGC triplet at the C-terminal; (2) causing a transfer between an SH group of the C-terminal cysteine and a carbonyl group of the glycine in the CGC triplet to obtain an R-X-CG-thioester; and (3) causing, in the R-X-CG-thioester, a transfer between the SH group of the cysteine and a carbonyl group of X, and a transfer between an amino group of the cysteine and a thiol group of the glycine to obtain a peptide thioester, and a method for producing a peptide using the peptide thioester produced by this method.

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

The present invention is related to the use of HMGB1 antagonists such as K883 in the treatment and/or prevention and/or inhibition of severe sepsis in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists in an effective amount to treat and/or prevent and/or inhibit this condition.